List of analysts that have been bullish recently on $AMRN. Of course lot of these are probably sell side research analysts and likely have some IB business with Amarin.
Jon LeCroy @ Hapoalim Securities
Thomas Wei @ Jeffries
Joseph Schwartz @ Leerink
Ritu Baral @ Canaccord Genuity
David Kestenbaum @ Morgan Joseph TriArtisan
David Kestenbaum @ Morgan Joseph TriArtisan 08/22/2011
Thomas Wei @ Jeffries 11/16/2011
Ritu Baral @ Canaccord Genuity 11/16/2011
"Reiterate rating and price target on commercial, partnership potential of AMR101. AMR101 is Amarin’s 96% EPA omega-3 drug for very high triglycerides (TG). AMRN submitted AMR101’s NDA for high TG in Q3/11. We think AMR101 will be approved mid-2012. We expect significant progress in IP and business development in H2/12." "Unclear how higher bioavailability will translate into TG/non--HDL--C reduction. While Epanova bioavailability data is compelling, experts noted they are still uncertain if it translates to greater triglyceride/non-HDL-C reduction."
Joseph Schwartz @ Leerink, 04/18/2011, 11/14/2011
Leerink Swann, which places its peak sales estimates for the drug at $3.2 billion by 2021, believes that the efforts of a pharma partner could drive sales even higher than that estimate.
Morgan Joseph TriArtisan 09/07/2011,11/08/2011
Morgan Joseph believes that concerns about Amarin's patent for AMR101 have been "unwarranted and overblown." The firm continues to expect the NDA filing for AMR101 in the hypertriglyceridemia indication to be accepted in coming weeks and it maintains a Buy rating. :
Jon LeCroy @ Hapoalim Securities , 01/18/2011
LeCroy thinks AMR101, Amarin’s lead product, could have peak annual sales of $1 billion and values a potential acquisition of them at around $4 billion. By the way, they have Amarin rated as a ‘Buy’ with a $12 price target.
(This is before Anchor results)